Incannex's IHL-42X Lowered AHI, ODI in Obstructive Sleep Apnea Phase 2 Trial
The clinical trial assessed three doses of IHL-42X at reducing the AHI in patients with OSA, as well as collected safety data.
Source: sleepreviewmag.com
Page 8 - Mark Bleackley News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Mark Bleackley. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Mark Bleackley Today - Breaking & Trending Today
Incannex announces positive results from phase 2 clinical trial investigating the effect of IHL-42X for treatment of obstructive sleep apnoea
Highlights: IHL-42X reduced primary endpoint apnoea hypopnea index relative to baseline at all three doses that were assessed Low dose IHL-42X exhibited...
Source: prnewswire.com
Incannex Meets with FDA in Pre-IND Meeting for Sleep Apnea Drug Candidate
Incannex characterized the pre-investigational new drug application (pre-IND) meeting about IHL-42X as “highly constructive.”
Source: sleepreviewmag.com
Incannex Healthcare Ltd has positive FDA pre-IND meeting on IHL-42X for obstructive sleep apnoea
Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) has completed a highly constructive Pre-Investigational New Drug (IND Application meeting with the US Food...
Source: proactiveinvestors.com
Incannex Announces Positive Pre-IND Meeting with U.S. FDA for IHL-42X for Obstructive Sleep Apnoea
/PRNewswire/ -- Incannex Healthcare Limited (NASDAQ: IXHL) (ASX: IHL), ('Incannex' or the 'Company') a clinical-stage pharmaceutical company developing unique...
Source: prnewswire.com